US Stock MarketDetailed Quotes
MIRA MIRA Pharmaceuticals
- 1.850
- -0.020-1.07%
Close Aug 23 16:00 ET
- 2.720
- +0.870+47.03%
Post 19:59 ET
27.34MMarket Cap-2199P/E (TTM)
1.930High1.825Low5.77MVolume1.930Open1.870Pre Close15.13MTurnover65.29%Turnover RatioLossP/E (Static)14.78MShares6.77052wk High12.33P/B16.35MFloat Cap0.51052wk Low--Dividend TTM8.84MShs Float7.980Historical High--Div YieldTTM5.62%Amplitude0.510Historical Low2.620Avg Price1Lot Size
MIRA Pharmaceuticals Stock Forum
Sign in to post a comment
$MIRA Pharmaceuticals (MIRA.US)$
MIRA Pharmaceuticals (NASDAQ:MIRA) has filed for a $100M mixed shelf offering composed of common stock, preferred stock, warrants and units, it said in a filing Aug. 13, 2024
The up to $19,268,571 of common stock that may be offered, issued, and sold under the sales agreement prospectus is included in the $100,000,000 of securities that may be offered, issued, and sold by MIRA Pharmaceuticals (MIRA) under the base prospectus.
The specific terms of any securi...
MIRA Pharmaceuticals (NASDAQ:MIRA) has filed for a $100M mixed shelf offering composed of common stock, preferred stock, warrants and units, it said in a filing Aug. 13, 2024
The up to $19,268,571 of common stock that may be offered, issued, and sold under the sales agreement prospectus is included in the $100,000,000 of securities that may be offered, issued, and sold by MIRA Pharmaceuticals (MIRA) under the base prospectus.
The specific terms of any securi...
1
5
$MIRA Pharmaceuticals (MIRA.US)$
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
2
$MIRA Pharmaceuticals (MIRA.US)$MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
$MIRA Pharmaceuticals (MIRA.US)$ US)
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials
1
$MIRA Pharmaceuticals (MIRA.US)$ Mira Pharmaceuticals- Showcases Significant Progress, Announces Final Phase of Regulatory Work as It Prepares for Ind Submission by Year-End
1
2
$MIRA Pharmaceuticals (MIRA.US)$
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Recepto
MIRA Pharmaceuticals (NASDAQ:MIRA) has unveiled new preclinical data on Ketamir-2's principal metabolite, Nor-Ketamir-2. The findings show that Nor-Ketamir-2 selectively interacts with the NMDA PCP site, demonstrating high selectivity and lack of activity on other sites. A new salt, Ketamir-2 Pamo...
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Recepto
MIRA Pharmaceuticals (NASDAQ:MIRA) has unveiled new preclinical data on Ketamir-2's principal metabolite, Nor-Ketamir-2. The findings show that Nor-Ketamir-2 selectively interacts with the NMDA PCP site, demonstrating high selectivity and lack of activity on other sites. A new salt, Ketamir-2 Pamo...
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
AddiBee0925 : so basically it will rise pretty well on Monday PM and then nosedive drastically with the execution of said offering. that's what I figuring
Rafey Jan OP : heheh... just putting the message out there, so everyone can make informed decisions about stock
LooseSpeculator : The offering is closed. Check the filing.
Rafey Jan OP : Are you saying they've sold up to 19 mill stock since auguest 13..?
B_jammin : I don't think they have at least not on the date of filing. I will read again but skimming over it appears they will sell from "time to time" within a 12 month period not greater than 1/3 of the public float.